Status:
COMPLETED
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
Lead Sponsor:
Federal University of São Paulo
Conditions:
Hypogonadotropic Hypogonadism
Prolactinoma
Eligibility:
MALE
18-70 years
Phase:
PHASE2
Brief Summary
Prolactinomas are usually associated with hypogonadotropic hypogonadism in both sexes. Clomiphene citrate is a well known selective estrogen receptor modulator that increases gonadotropin secretion vi...
Eligibility Criteria
Inclusion
- a minimum follow-up of 6 months under DA therapy with normal serum prolactin or with maximum DA dose (3.5 mg/week of cabergoline or 10 mg/day of bromocriptine for at least 2 months)
- serum total testosterone less than 300ng/dl with normal or low LH and FSH levels after discontinuing testosterone replacement for at least 2 months.
Exclusion
- impossibility to attend scheduled visits and irregular compliance to DA treatment.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00697814
Start Date
June 1 2004
End Date
June 1 2005
Last Update
June 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuroendocrine Unit - Escola Paulista de Medicina (UNIFESP)
São Paulo, São Paulo, Brazil, 09541-330